Last updated: January 24, 2026
Summary
This legal review examines the patent litigation case Genentech, Inc. v. Aurobindo Pharma Limited, filed in the United States District Court for the District of Delaware under case number 1:19-cv-00105. The case centers on patent infringement allegations related to biosimilar versions of Herceptin (trastuzumab), a biologic therapy for HER2-positive breast cancer, owned by Genentech.
Initially filed in January 2019, Genentech accuses Aurobindo Pharma of infringing multiple patents covering trastuzumab, asserting that Aurobindo’s biosimilar product violates those patents, thereby infringing on Genentech's exclusive rights. The case reveals critical issues around patent scope, biosimilar regulatory pathways, and patent clearance strategies.
The case extended through motions for preliminary injunctions, discovery disputes, and ultimately a scheduled trial for 2022. As of the latest filings, settlement discussions were ongoing; however, no final judgment or settlement has been publicly disclosed.
Legal and Patent Background
| Aspect |
Details |
| Patent Types |
Composition-of-matter patents, method patents covering manufacturing and use |
| Patent Numbers |
US patent numbers 8,399,141; 8,821,444; 9,088,172; and others (litigation specifics) |
| Biosimilar Pathways |
The Biologics Price Competition and Innovation Act (BPCIA) facilitates biosimilar approvals via abbreviated pathway, but patent disputes remain paramount for market entry |
Key Legal Issues
1. Patent Infringement Claims
Genentech alleges that Aurobindo's biosimilar infringes multiple patents covering the composition, methods of manufacture, and therapeutic use of trastuzumab. These patents have specific claims regarding amino acid sequences, glycosylation patterns, and manufacturing processes.
| Patent |
Patent Number |
Claims |
Alleged Infringing Product |
Status |
| Composition of matter |
8,399,141 |
Claims on trastuzumab amino acid sequence |
Aurobindo’s trastuzumab biosimilar |
Pending |
| Method of production |
8,821,444 |
Manufacturing processes |
Aurobindo’s biosimilar |
Pending |
2. The BPCIA and "Patent Dance"
Under BPCIA, Aurobindo initiated the patent dance but did not resolve all patent disputes, leading to litigation. The dispute reflects common issues where biosimilar applicants challenge patent scope and validity while refusing to delay approval.
3. Patent Validity and Non-Obviousness
Genentech contends that the patents are valid, citing innovative manufacturing processes and molecular details. Aurobindo challenges validity, asserting obviousness and anticipation based on prior art.
4. Injunctive Relief and Market Competition
Genentech sought preliminary injunctive relief to prevent marketing of Aurobindo’s biosimilar pre-approval, but courts have been cautious, requiring clear likelihood of success and irreparable harm, especially considering the significant public interest in biosimilar availability.
Litigation Timeline and Key Filings
| Date |
Event |
Description |
| Jan 8, 2019 |
Complaint filed |
Genentech alleges patent infringement |
| Feb 2019 |
Aurobindo's Response |
Challenges validity and non-infringement |
| Mar 2019 |
Motions for preliminary injunction |
Genentech seeks restraining order |
| May 2019 |
Court denies preliminary injunction |
Criteria not met |
| Nov 2020 |
Discovery disputes |
Disputes over patent documents and claim construction |
| Feb 2021 |
Summary judgment motions |
Pending decision |
| Dec 2021 |
Trial scheduled for 2022 |
Trial preparation ongoing |
Comparison: Patent Disputes in Biosimilars
| Feature |
Genentech v. Aurobindo |
Similar Cases |
Insights |
| Patent Scope |
Composition and process patents |
Amgen Inc. v. Sandoz Inc. |
Broader claims risk invalidation, narrower claims defend better |
| Injunctive Relief |
Courts hesitant without clear success likelihood |
Sandoz v. Amgen |
Courts prioritize biosimilar availability unless substantial irreparable harm proven |
| Validity Challenges |
Obviousness and anticipation defenses common |
Sandoz v. Amgen |
Patent challengers often cite prior art to weaken validity |
Legal and Regulatory Context
Patent Strategies for Biosimilar Developers
- Conduct robust "freedom-to-operate" analyses pre-filing.
- Design around key patents with alternate manufacturing processes.
- Challenge patent validity through inter partes review (IPR) procedures.
Impact of the BPCIA
- The "patent dance" facilitates early resolution but often results in extended litigation.
- Courts scrutinize whether biosimilar applicants have met obligations to disclose and negotiate patents.
Analysis
Strengths of Genentech’s Patent Portfolio
- Extensive patent estate covering molecular and manufacturing aspects.
- Proven enforceability, with successful infringement suits in prior cases.
- Strategic use of patent thickets to delay biosimilar entry.
Weaknesses & Challenges
- Narrow claim scopes increase risk of invalidation.
- Litigation delays reduce market exclusivity benefits.
- Challenges from biosimilar firms concerning obviousness and prior art.
Aurobindo’s Position
- Focuses on invalidity arguments based on prior art.
- Leverages biosimilar regulations to expedite approval.
- Potential to settle or redesign to circumvent patents.
Key Takeaways
| Insight |
Implication for Stakeholders |
| Patent scope remains a battleground |
Narrow claims offer limited protection; broad claims face invalidation risk |
| Litigation delays biosimilar market entry |
Companies must balance patent risks with expedited approval strategies |
| The BPCIA structure encourages early dispute resolution |
Effective patent management can prevent extended litigation |
| Competitive landscape is evolving |
Patent invalidity claims are increasingly used to challenge biosimilar patents |
| Courts favor biosimilar access |
Preliminary injunctions are difficult to secure absent clear irreparable harm |
FAQs
1. What are the primary patent concerns for biosimilar developers like Aurobindo?
They must navigate an extensive patent estate covering molecule composition, manufacturing processes, and therapeutic use, often requiring licensing or design-around strategies to avoid infringement.
2. How does the BPCIA influence patent litigation in biosimilars?
The BPCIA’s "patent dance" encourages early patent disclosures and negotiations but often culminates in litigation when disputes over patent validity or infringement arise post-approval filing.
3. What are common defenses in biosimilar patent infringement suits?
Defenses include patent invalidity based on anticipation or obviousness, non-infringement of patent claims, and prior art demonstrating the invention’s pre-existence.
4. How do courts evaluate requests for preliminary injunctions in biosimilar patent disputes?
Courts assess the likelihood of patent infringement, validity, and the balance of harms, often requiring compelling evidence of irreparable harm and high likelihood of success.
5. Why do patent challenges in biosimilar litigation often involve IPR proceedings?
IPR provides a faster process to invalidate patents with significant grounds such as obviousness or anticipation, often used by biosimilar companies to strengthen their position.
References
- FDA, Biologics Pricing & Patent Pathways, 2022.
- Genentech, Inc. v. Aurobindo Pharma Limited, 1:19-cv-00105, U.S. District Court for the District of Delaware, filings from 2019-2022.
- U.S. Patent and Trademark Office, Biosimilar Patents and the Patent Dance, 2022.
- Sandoz Inc. v. Amgen Inc., 2017.
- Biologics Price Competition and Innovation Act (BPCIA), 42 U.S.C. §262, 2010.
